Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation (GERN) is a clinical-stage biopharmaceutical company advancing novel oncology therapies through its telomerase inhibitor research. This page provides investors and industry professionals with verified updates on clinical developments, regulatory milestones, and strategic initiatives.
Access the latest press releases and analysis related to imetelstat's progress in treating hematologic malignancies like myelodysplastic syndromes. Our curated collection ensures you stay informed about trial results, partnership announcements, and scientific presentations without speculative commentary.
Key updates include details on Phase 3 clinical trials, FDA communications, intellectual property developments, and collaboration agreements. All content is sourced directly from official company channels to maintain accuracy and compliance.
Bookmark this page for streamlined access to Geron's evolving story in cancer therapeutics. Check back regularly for objective reporting on advancements in telomerase-targeted treatment approaches.
Geron Corporation (NASDAQ: GERN) announced the granting of stock options to purchase 901,950 shares of common stock to newly hired employees as an inducement for employment. The options were issued on September 21, 2022, at an exercise price of $2.54 per share, equal to the stock's closing price on that day. Of the total, 495,800 shares vest over four years while 406,150 shares vest upon achieving specific regulatory milestones. This grant aligns with Nasdaq rules and Geron's 2018 Inducement Award Plan.
Geron Corporation (NASDAQ: GERN) appointed John F. McDonald to its Board of Directors effective September 7, 2022. McDonald, a seasoned executive with over 30 years in the biopharmaceutical industry, aims to enhance Geron's strategic and commercial objectives, particularly in advancing imetelstat. His past roles include leadership positions at Novo Nordisk and Biogen. The company's clinical focus remains on the telomerase inhibitor, imetelstat, currently undergoing two Phase 3 trials for hematologic malignancies, with top-line results expected in early January 2023.
Geron Corporation (Nasdaq: GERN) has announced that CEO John A. Scarlett will present at three major investor conferences in New York City. The events include the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, and the Baird 2022 Global Healthcare Conference on September 14, 2022. Webcasts will be available on Geron's website and archived for 30 days. Geron focuses on developing its first-in-class telomerase inhibitor, imetelstat, for treating hematologic malignancies.
Geron Corporation (NASDAQ: GERN) has initiated the IMproveMF Phase 1 study, aimed at evaluating the combination of imetelstat and ruxolitinib in frontline myelofibrosis patients. Preclinical data indicated promising effects of this combination. The study will assess safety, pharmacokinetics, and clinical activity, with the first patient already dosed. Results are anticipated by late 2023. Imetelstat, a first-in-class telomerase inhibitor, shows potential in modifying disease progression in myelofibrosis, setting it apart from existing treatments.
Geron Corporation (NASDAQ: GERN) announced the granting of non-statutory stock options for 365,800 shares to new employees as part of their employment inducement. The options were granted on August 17, 2022, at an exercise price of $2.15 per share, equivalent to the closing stock price on that date. These options have a 10-year term and vest over four years, rewarding continued employment. This grant follows Nasdaq Listing Rule 5635(c)(4) and is part of Geron's 2018 Inducement Award Plan.
Geron Corporation (NASDAQ: GERN) has reported its financial results for Q2 2022, marking a net loss of $28.1 million, or $0.07 per share. Revenue for the quarter stood at $73,000, down from $107,000 in Q2 2021. The company maintains a strong balance sheet with $220 million in cash and marketable securities and has amended its loan facility to secure an additional $50 million. Key upcoming milestones include Phase 3 trial results for lower risk MDS expected in January 2023, U.S. regulatory submissions planned for 2023, and a potential commercial launch of imetelstat in 2024.
Geron Corporation (NASDAQ: GERN) will release its Q2 2022 financial results on August 11, 2022, after the market closes. The details will be available on the company’s website. A conference call to discuss these results and upcoming milestones is scheduled for 4:30 p.m. ET on the same day. The call will be accessible via a live webcast on their site, with an archive available for 30 days. Geron is focused on developing its telomerase inhibitor, imetelstat, for hematologic malignancies and is conducting two Phase 3 trials.
Geron Corporation (Nasdaq: GERN), a biopharmaceutical firm focused on hematologic malignancies, announced that CEO John A. Scarlett will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022, at 12:35 p.m. ET. The event will be webcasted through the Investor Relations section on Geron's website and will be available for replay for 30 days post-event. Geron is currently advancing two Phase 3 trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis.
Geron Corporation (Nasdaq: GERN) has granted non-statutory stock options for 405,800 shares to new employees as part of their employment inducements. These options, issued on July 20, 2022, have an exercise price of $1.94 per share, matching the stock's closing price on the grant date. They feature a 10-year term and vesting over four years. Geron is focused on developing imetelstat, a telomerase inhibitor, for hematologic malignancies, with two ongoing Phase 3 clinical trials: IMerge and IMpactMF.
Geron Corporation announces an expansion of its loan facility with Hercules Capital and Silicon Valley Bank, increasing access from $75 million to $125 million. This amendment allows for an additional $50 million in potential non-dilutive capital in 2023, crucial for the company as it anticipates top-line results from the Phase 3 IMerge trial in January 2023. Funding aims to support operations and potential commercialization of imetelstat until mid-2024.
